Specifically, two tyrosine kinase inhibitors (TKI), the VEGFR2/EGFR inhibitor vandetanib and VEGFR2/MET inhibitor cabozantinib, are approved for treatment of advanced thyroid cancer, and have been evaluated in clinical trials for RET-associated lung adenocarcinoma (Wells et al., 2012; Drilon et al., 2016, 2018a; Schlumberger et al., 2017; Yoh et al., 2017). The gene discussed is RET; the disease is thyroid gland carcinoma.